auto_awesome_motion View all 5 versions
organization

Medical University of Sofia

Country: Bulgaria
10 Projects, page 1 of 2
  • Open Access mandate for Publications
    Funder: EC Project Code: 882247
    Overall Budget: 182,722 EURFunder Contribution: 182,722 EUR
    Partners: Medical University of Sofia

    c-Src, the first proto-oncogene to be identified, controls many aspects of tumor biology including the capacity of the cancer cells to multiply, survive, and metastasize. We recently discovered that c-Src forms dimers and that dimerization is essential for the activity of the enzyme. This represents a significant paradigm shift in our understanding of the biology of Src family kinases, which until recently were assumed to function as monomeric proteins. The discovery that c-Src functions as a dimer creates the basis for development of a novel class therapeutics in principle based on disruption of Src dimerization. Our preliminary data indicate that such dimerization inhibitors have dramatic anti-tumor activity, suggesting that the proposed research may lead to development of an effective anti-cancer therapy. The project goal is to accomplish the following specific objectives: 1. To determine the efficacy of inhibition of Src myristoylation and dimerization for treatment of cancer; 2. To develop competitive inhibitors of Src dimerization and activity. The project will also create opportunities of boosting the research and innovation capacity of Europe, for obtaining IPRs, commercialization, and setting new collaborations with top US research institutions and companies. The proposal is intended as a career development fellowship that is designed to facilitate my reintegration into the EU science and to further my career towards a leading independent research position. I am confident that the quality and excellence of science produced and the new research and complementary skills obtained during the fellowship will serve as a cornerstone for my future career advancement and mark the beginning of my new laboratory and research program.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101071321
    Overall Budget: 1,998,760 EURFunder Contribution: 1,998,760 EUR
    Partners: University of Chieti-Pescara, University of Oviedo, HOCHSCHULE KARLSRUHE, TUIAŞI, Medical University of Sofia, MUNSTER TECHNOLOGICAL UNIVERSITY, HOGSKOLAN I SKOVDE, UR

    The BI4E project is born out from the IngEniUm Alliance of European Universities with the ambition of enhancing the existing inter-university cooperation between the partner Universities, as well as with other entities (both international and local), and to strengthen the Higher Education Institutions (HEIs) capacity to meet the diverse challenges faced by the Higher Education System and Institutions: the twin green and digital transition, the fight against climate change, the achievement of the Agenda 2030 SDGs, all of them profound societal challenges the Universities must be ready to address. The BI4E project intends to give a boost to the Alliance, making it an effective instrument to promote excellence in the partner HEIs, particularly targeted to the alliance members in the widening countries, the Gheorghe Asachi Technical University of Iasi and the Medical University – Sofia, and involving leading HEIs from six different Member States. This BI4E project is particularly focusing on the research and innovation missions, completing the strategic and operational capacities of the partners, especially those from the widening countries. BI4E activities will directly touch six out of the seven “transformation modules” proposed by the Policy Report ‘Towards a 2030 Vision on the Future of Universities in Europe’. The project will improve HEI capacity to address major challenges, through the implementation of strategic planning adapted to their needs, institutional transformation, cooperation in terms of research, fostering entrepreneurship and the promotion of international scientific careers. The project will help to build closer cooperation links between the partners that will facilitate the exchange of information, knowledge and experience. At the end of the project the Alliance will be much more prepared to become a fully operational European University Alliance, in which cooperation in education and research will be carried out seamlessly.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101072377
    Funder Contribution: 2,642,600 EUR
    Partners: INRAE, UMC, DTU, PEI, PLUS, HF, Medical University of Vienna, Medical University of Sofia, Luxembourg Institute of Health

    Introduction of novel foods, such as insects, will strongly contribute to the security and sustainability of our food supply. However, these novels foods need to be safe (EU regulation 2015/2283). Allergenicity assessment is an essential part of the safety assessment of novel foods. Unfortunately, current methods to assess de novo allergenicity lack predictive power and are not validated. Consequently, food producers and risk assessors struggle with allergenicity assessment, slowing down the introduction of novel foods in our food supply. Enabling the safe introduction of novel foods, while protecting humans from unacceptable food allergy risks, calls for a multidisciplinary approach. The ALLPreT consortium is a highly multidisciplinary group of experts from universities, research institutes, hospitals, patient organisations and industry arising from the EU COST Action ImpARAS (Improved Allergenicity Risk Assessment Strategy). This puts them in an ideal position to consolidate their previous collaboration and set up an innovative doctoral training network in this area. The overall goal of ALLPreT is to train the next generation of scientists who can tackle the shortcomings in the current food allergy assessment of novel food products. ALLPreT will train early stage researchers (ESRs) in the core aspects of food allergy risk assessment, immunology, protein chemistry, bioinformatics, in vitro/in vivo/in silico model development and complementary “soft” skills to deliver well educated young scientists, with a unique position within the EU labour market. The ESRs will explore the new field of research on de novo sensitisation by novel foods and develop a toolbox of in vitro/in vivo/in silico allergenicity prediction tools that are scientifically sound, validated and easily usable by industry and food safety authorities. This toolbox will contribute to fast and accurate safety assessment, thereby speeding up safety approval and market uptake of novel foods.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 964997
    Overall Budget: 1,999,930 EURFunder Contribution: 1,999,930 EUR
    Partners: UT, Vilnius University, BIOMEDICAL RESEARCH CENTER OF THE SLOVAK ACADEMY OF SCIENCES, Medical University of Sofia, UL, OSI, Semmelweis University, MEFZG, CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, MU...

    The gap in Research and Innovation (R&I) performance, which persists despite considerable investments from the European Structural and Investment Funds (ESIF) in the lower-performing regions of the EU, is an issue with major socio-economic and political consequences. In Health R&I the gap has a profound impact on distribution of funding from the EU Framework Programmes as well as on hindering the EU-wide impact of R&I on health and quality of life. With A4L_ACTIONS, we aim to address roots of this situation in the lower-performing Central and Eastern Europe (CEE) by improving culture, governance, recognition and innovation potential of the health research-performing institutions. Our goal is to increase their attractiveness for collaborations with advanced Europe and create spill-over effects in the whole region. As the Alliance4Life, we are an established network of progressive health research institutions in CEE and a source of successfully piloted good practice. By building upon our results and impact achieved so far, we will convert our recommendations and strategies into actions as follows: - Culture fostering excellence: piloting peer-evaluation and assessment of institutional practice as a strategic management tool, professionalizing research administration; - Recognition and trust towards CEE: attracting advanced partners to identified pockets of excellence, supporting scientific ideas originating in CEE, initiating new international projects and collaborations with industry; - Career policy nurturing talent: training and networking next generation of leaders, upgrading institutional career systems; - Impact on innovation: raising the competences of Technology Transfer specialists, creating industry relations platform linking academia and industry; - Spill-over effects: sharing, inspiring, communicating with stakeholders and policy makers; using the established networks to gain advice, new collaborations and EU-wide impact.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 825162
    Overall Budget: 9,640,780 EURFunder Contribution: 9,640,780 EUR
    Partners: University of York, Utrecht University, Medical University of Sofia, SYREON, UB, UPM, NICE, EORTC, Zorginstituut Nederland, University of Oulu...

    HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and real-time decision-making for integrated healthcare throughout Europe. HTx will focus on therapeutic areas with high unmet need for which HTA information has to be provided on complex and personalised combinations of health technologies. Based on a select number of relevant case studies, HTx will enhance methods for integrating evidence from RCTs and real-world data (RWD). HTx will also augment statistical and econometric methods for generating robust estimates of effectiveness and cost-effectiveness in order to support relevant HTA decision-making for these complex and personalised combinations of health technologies. HTx will also contribute to improving methods to support personalised treatment advice fitted for sharing with patients and their physicians. This includes the development of statistical and econometric approaches and artificial intelligence/machine learning methods for forecasting treatment effects in specific groups of patients. Simultaneously, in close collaboration with the European Network for HTA (EUnetHTA), HTx will improve synergies between regulatory agencies, HTA bodies and clinical guideline developers. This will include the translation of HTx methods into already existing European guidelines, most prominently those developed by EUnetHTA. HTx will also support initial efforts to discuss reimbursement and funding models that facilitate controlled access to and the pricing of these complex health technologies. Finally, we will evaluate the transferability of HTx results into all EU Member Countries especially in Central and Eastern European (CEE) Countries and promote the dissemination of HTx results to the different European stakeholders with a special focus on the patient community.